NICE rejects Roche’s new breast cancer drug over high pricing
The NHS drug advisory body National Institute for Health and Care Excellence (NICE) has rejected Roche’s new breast cancer drug Kadcyla (trastuzumab emtansine) because of the treatment's high cost.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Health | Herceptin | National Institute for Health and Clinical Excelle | Pharmaceuticals